All In Biotech

Drug Trial Radar · NCT07625618

A Pharmacokinetic and Safety Study of MY008211A Tablets in Subjects With Impaired or Normal Hepatic Function

Last checked: Nov 20, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Sep 20, 2024

Primary completion

Dec 28, 2024

Study completion Dec 28, 2024

Sponsor

Sponsor type
Industry
First posted
Jun 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a single-center, non-randomized, open-label, parallel, single-dose study to evaluate the PK profile and safety of MY008211A Tablets in subjects with hepatic impairment.

Conditions

  • Hepatic Insufficiency (MeSH ID: D048550)

Interventions

  • MY008211A tabletsDrug

    Each subject will take a single oral dose of 400 mg MY008211A Tablets under fasting conditions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: up to 12 weeks
  2. AUC0-lastTime frame: up to 12 weeks
  3. AUC0-infTime frame: up to 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Hospital of Jilin University

    Jilin City, Changchun, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.